Travere reports ~$74M preliminary Q4 net product sales; FILSPARI PSFs up 40% QoQ

Travere Therapeutics, Inc.

2024-FY EPS reported -$4.08 revenue$233,175,000

Preliminary Q4 2024 FILSPARI net sales ~$50M; total Q4 net product sales ~$74M; FY2024 ~$227M.
Received 693 new FILSPARI patient start forms in Q4, a 40% sequential increase in net sales vs Q3.
Cash, equivalents and marketable securities ~$371M at year-end 2024.
FDA accepted sNDA to modify liver monitoring for FILSPARI in IgAN; PDUFA date Aug 28, 2025.
On track for FSGS regulatory pathway update by Q4 2024 earnings call; partner CSL Vifor milestone $17.5M upon European full approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.